2019全球IBD干预小组立场声明_生物治疗时代炎症性肠病内镜干预的作用.pdfVIP

REVIEW ARTICLE Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group Bo Shen, MD,1 Gursimran Kochhar, MD,2 Udayakumar Navaneethan, MD,3 Xiuli Liu, MD, PhD,4 Francis A. Farraye, MD, MSc,5 Yago Gonzalez-Lama, MD,6 David Bruining, MD,7 Darrell S. Pardi, MD, MS,7 Martin Lukas, MD,8 Martin Bortlik, MD,8 Kaicun Wu, MD, PhD,9 Ajit Sood, MD, 10 David A. Schwartz, MD,11 William J. Sandborn, MD 12, on behalf of the Global Interventional Inflammatory Bowel Disease Group Cleveland Ohio; Pittsburgh, Pennsylvania; Orlando, Gainesville, Florida; Boston, Massachusetts; Rochester, Minnesota; Nashville, Tennessee; San Diego, California, USA; Madrid, Spain; Praha, Czech Republic; Xi’an, China; Ludhiana, India Interventional (or therapeutic) inflammatory bowel disease (IBD) endoscopy has an expanding role in the treat- ment of disease and surgical adverse events. Endoscopic therapy has been explored and used in the management of strictures, fistulas/abscesses, colitis-associated neoplasia, postsurgical acute or chronic leaks, and obstructions. The endoscopic therapeutic modalities include balloon dilation, stricturotomy, stent placement, fistulotomy, fis- tula injection and clipping, sinusotomy, EMR, and endoscopic submucosal dissection. With a better understanding of the disease course of IBD, improved long-term impact of medical therapy, and advances in endoscopic tech- nology, we can foresee interventional IBD becoming an integrated part of the multidisciplinary approach to patients with complex IBD. (Gastrointest Endosc 2019;89:215-37.) The past decades have witnessed rapid advances in med- approval of tofacitinib. The long-term impa